News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Callum Hawes

Advertisement

Callum Hawes is Director, Commercial Content Strategy at Veeva Systems

Articles by Callum Hawes

Make Content Work Harder from Start to Finish

ByCallum Hawes
May 25th 2020

A centralized platform for assets supports the industry’s need for a greater volume of more diverse content, writes Callum Hawes.

Advertisement

Latest Updated Articles

  • Make Content Work Harder from Start to Finish
    Make Content Work Harder from Start to Finish

    May 25th 2020



Advertisement
Advertisement

Trending on PharmExec

1

Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock

2

Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio

3

Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science

4

FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement

5

How Have Recent Regulatory Actions Impacted the Rare Disease Space?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us